Clinical Trial Update: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating atezolizumab with cobimetinib or idasanutlin in stage IV or unresectable recurrent estrogen receptor-positive breast cancer; study ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Unresectable Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Idasanutlin (Idasanutlin)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-08-11